BBOT earnings analysis
What we found in BBOT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
BBOT remains a development-stage biotechnology company with no revenue and a substantially worsening loss profile: six-month net loss was $98.6 million versus $50.5 million a year earlier, while reported diluted EPS was negative $705.20. The company has meaningful liquidity runway into 2028 and is advancing three candidates in Phase 1 trials, but management acknowledges that current resources will not fund all candidates through approval and that additional capital may be needed. Sole-source manufacturing exposure, recent management changes and continued clinical and regulatory uncertainty keep the risk/reward profile bearish.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Clinical investment is accelerating
- The company reported diluted EPS of negative $705.20 for the quarter and a six-month net loss of $98.6 million, compared with a six-month net loss of $50.5 million in the prior-year period.
- Cash runway extends into 2028
- Management estimates cash, cash equivalents and marketable securities will fund operating expenses and capital expenditures into 2028, providing a multi-year operating runway.
- Three programs in Phase 1 trials
- The company is conducting Phase 1 clinical trials for three candidates: BBO-8520, BBO-10203 and BBO-11818.
- Preliminary data support pipeline progress
- BBOT reported positive preliminary safety and antitumor data across its three RAS and PI3Kα programs on January 7, 2026, including BBO-8520, BBO-11818 and BBO-10203.
- Controls remained effective
- Management reported that internal controls over financial reporting were effective as of June 30, 2026, with no changes during the quarter that materially affected, or were reasonably likely to materially affect, controls.
- Organization supports pipeline execution
- The company had 88 full-time employees as of June 30, 2026, supporting research, development and administrative activities.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Losses and cash burn remain substantial
- The six-month net loss increased to $98.6 million from $50.5 million in the prior-year period, and accumulated deficit reached $455.1 million as of June 30, 2026. The company expects significant and increasing expenses and operating losses for the foreseeable future.
- Additional capital will likely be required
- Management states that existing cash and marketable securities will not be sufficient to fund all product candidates through regulatory approval, and the company has no committed external source of funds. Additional financing could dilute stockholders or restrict operations.
- Sole-source manufacturing exposure
- The company primarily relies on sole-source suppliers for API, drug product and starting materials; redundant or second-source supply is not currently in place, although manufacturing with a second source is expected to begin in 2026.
- UCSF payment dispute remains unresolved
- UCSF asserts that an Indexed Milestone Payment of less than $5.0 million may become due following the Business Combination closing, while BBOT disputes the interpretation and believes no payment is due.
- Recent management transition
- The company disclosed management turnover in April 2026: Pedro Beltran became CEO, Idan Elmelech became COO, Neil Kumar became Executive Chairman, and CFO Uneek Mehra departed effective April 30, 2026.
- New ERP creates execution risk
- The company implemented a new ERP system on January 1, 2026 and warns that implementation issues could cause delayed reporting, billing errors or accounting errors.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-705.2
What they said about what is next.
No quantitative revenue or EPS guidance was provided. Management estimates existing cash, cash equivalents and marketable securities will fund operating expenses and capital expenditures into 2028; the estimate excludes potential product revenue and does not fund all candidates through regulatory approval.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 12, 2026
- BridgeBio Oncology Therapeutics, Inc. (BBOT) reported a Q1 2026 net loss of $42.1 million, with an EPS of -$526.11, missing expectations significantly. R&D expenses surged by 93% year-over-year, reflecting heightened…
- 10-K · March 5, 2026
- BridgeBio Oncology Therapeutics (BBOT) is a clinical-stage oncology company advancing three internally discovered oral small‑molecule programs targeting RAS and PI3Kα (BBO-8520, BBO-11818, BBO-10203). The company…
- 10-Q · August 1, 2025
- Helix Acquisition Corp. II (the SPAC sponsor of the proposed BBOT transaction) reported no operating revenue and generated net income of $918,310 for the three months ended June 30, 2025 (diluted EPS $0.04) driven by…
- 10-Q · August 14, 2024
- Helix Acquisition Corp. II is a blank‑check company (SPAC) that completed an IPO on February 13, 2024 and, as of June 30, 2024, has not commenced operating operations. The company holds the IPO proceeds in a Trust…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BBOT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever